Bone Marrow Failure, Trauma
Conditions
Keywords
Trauma, spinal cord, autoimmunity, antibody
Brief summary
The purpose of the study is to detect the presence of autoantibodies and autoantigens in cerebrospinal fluid early (\<48 hours) following spinal cord trauma. The study also aims to define the central or peripheral origin of autoantibodies by looking for their simultaneous presence at the blood level and to evaluate the prognostic value of the presence of autoantibodies within the cerebrospinal fluid, as well as on the initial clinical severity than on the recovery potential.
Interventions
None listed
Sponsors
University Hospital, Lille
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Patients with spinal cord injury dating back less than 48 hours 2. Men or women over 18 years of age 3. Patients benefiting from social protection 4. Surgery performed within 48 hours of the trauma 5. Informed and signed consent by the patient or trusted person
Exclusion criteria
1. Contra-indication to ensure surgical decompression within the first 48 hours following the trauma 2. Coagulation disorders or any condition that may make the lumbar puncture risky (eg, history of lumbar surgery) 3. Severe cranial trauma associated 4. History of autoimmune pathology 5. Immunosuppressive therapy or long-term corticosteroid therapy 6. Patients unable to comply with protocol requirements 7. Person benefiting from legal protection (guardianship / curator) 8. Person deprived of liberty 9. Patient unable to express consent 10. Pregnant women
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Level of anti glial fibrillary acid protein antibodies | The sampling is performed at the initial stage, i.e. within 48 hours after trauma. The time between trauma and sampling is specified and measured in hours. | Anti glial fibrillary acid protein antibodies measured into the cerebrospinal fluid |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Blood level of anti glial fibrillary acid protein antibodies | The sampling is performed at the initial stage, i.e. within 48 hours after trauma. The time between trauma and sampling is specified and measured in hours. | Anti glial fibrillary acid protein antibodies measured into the blood |
| Severity of Neurological Impairment | in the initial phase, at day 7, at 1 months, 3 months, 6 months and 1 year | Measured using the American Society Injury Association score |
Outcome results
None listed